8 completed, 4 unknown, 2 terminated, 1 withdrawn. 15 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 8, Unknown 4, Terminated 2, Withdrawn 1 |
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Renal Impairment: new trials by email Literature Review of Renal Impairment trials Research Report on Renal Impairment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor Isatuximab, Pomalidomide, Dexamethasone - Multiple Myeloma, Renal Impairment | Phase 2 | Unknown | Hellenic Society of Hematology | 108 | 2022-05-01 | 2022-03-28 |
| A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment Isatuximab, Bortezomib, Cyclophosphamide - Multiple Myeloma, Renal Impairment | Phase 2 | Unknown | Hellenic Society of Hematology | 51 | 2022-04-01 | 2022-03-29 |
| Neuromuscular Blockade in Patients With Severe Renal Impairment Cisatracurium + Neostigmine, Rocuronium + Sugammadex - Neuromuscular Blockade, Renal Impairment | Phase 2 | Completed | University of Texas Southwestern Medical Center | 49 | 2019-12-10 | 2023-11-08 |
| PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function Melflufen, Dexamethasone - Renal Impairment, Multiple Myeloma | Phase 2 | Terminated | Oncopeptides AB | 35 | 2018-08-28 | 2023-03-10 |
| Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function. LIK066 - Renal Impairment | Phase 2 | Completed | Novartis Pharmaceuticals | 53 | 2017-04-28 | 2021-01-05 |
| An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis. Simeprevir (SMV) 150 mg, Daclatasvir (DCV) 60 mg - Renal Impairment, End-stage Renal Disease | Phase 2 | Withdrawn | Janssen R&D Ireland | 2015-05-01 | 2015-07-17 | |
| Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3) Tadalafil, Placebo - Cardiomyopathy, Renal Impairment | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2014-03-01 | 2020-10-28 |
| Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2) Tadalafil, Placebo - Cardiomyopathy, Renal Impairment | Phase 1 / Phase 2 | Completed | Mayo Clinic | 20 | 2014-01-09 | 2021-06-11 |
| CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation delayed, low-dose CNI, BU-CNI, BU-Everolimus - Renal Impairment, Liver Transplantation | Phase 2 / Phase 3 | Unknown | University of Regensburg | 45 | 2011-06-01 | 2011-07-01 |
| Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment Febuxostat, Placebo - Renal Impairment | Phase 2 | Completed | Takeda | 96 | 2010-04-01 | 2013-09-25 |
| Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study Sodium bicarbonate, Sodium chloride - Systemic Inflammatory Response Syndrome, Oliguria | Phase 2 | Completed | Austin Health | 70 | 2010-02-01 | 2014-06-30 |
| Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients Vildagliptin - Renal Impairment, Diabetes | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 96 | 2008-12-01 | 2020-12-17 |
| Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females 50 mg Proellex - Renal Impairment | Phase 1 / Phase 2 | Terminated | Repros Therapeutics Inc. | 6 | 2008-10-01 | 2014-08-25 |
| Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study Albumin - Renal Impairment, All Cause Mortality | Phase 2 | Unknown | Hospital de Clinicas de Porto Alegre | 43 | 2006-03-01 | 2010-06-07 |
| Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients rolofyline, Comparator Placebo (unspecified) - Congestive Heart Failure, Renal Impairment | Phase 2 | Completed | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 160 | 2004-12-01 | 2008-04-04 |
Renal Insufficiency (15) · Multiple Myeloma (3) · Blood Protein Disorders (2) · Cardiomyopathies (2) · Hematologic Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Paraproteinemias (2) · Diabetes Mellitus (1) · Gout (1) · Heart Failure (1) · Hyperuricemia (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1)
Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Male Urogenital Diseases (15) · Urogenital Diseases (15) · Urologic Diseases (15) · Kidney Diseases (14) · Cardiovascular Diseases (6) · Heart Diseases (3) · Hemic and Lymphatic Diseases (3) · Hemorrhagic Disorders (3) · Hemostatic Disorders (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Pathologic Processes (3)
Dexamethasone (3) · Tadalafil (2) · isatuximab (2) · Acetaminophen (1) · Albumins (1) · Bortezomib (1) · Cyclophosphamide (1) · Diphenhydramine (1) · Febuxostat (1) · L-melphalanyl-p-L-fluorophenylalanine ethyl ester (1) · Lenalidomide (1) · Neostigmine (1) · Ranitidine (1) · Rocuronium (1) · Saline Solution (1)
Hellenic Society of Hematology (2) · Mayo Clinic (2) · Novartis Pharmaceuticals (2) · Austin Health (1) · Hospital de Clinicas de Porto Alegre (1) · Janssen R&D Ireland (1) · NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Oncopeptides AB (1) · Repros Therapeutics Inc. (1) · Takeda (1) · University of Regensburg (1) · University of Texas Southwestern Medical Center (1)
United States (6) · Greece (3) · Australia (1) · Brazil (1) · Czechia (1) · France (1) · Germany (1) · Poland (1) · Russia (1) · Spain (1)
Evangelos Terpos, Prof (2) · Horng H Chen, MD (2) · Alexandre Araujo (1) · Andre van As, MD, PhD (1) · Andreas A Schnitzbauer, MD (1) · Gabriela Rossi (1) · Hans J Schlitt, MD (1) · Michael C Reade, MBBS DPhil (1) · Nerina Harley, MBBS FCICM (1)
PMID 26894653, PMID 35001638, PMID 37295665
2008 (1), 2014 (1), 2016 (1), 2018 (1)